May fills a recent vacancy on the board for an independent member, following the departure of Michael Mulroy, which was not because of a disagreement with AgeX on any matter relating to company operations, policies, or practices.
He is president and CEO of Canada's Centre for Commercialization of Regenerative Medicine, a leading and highly successful public-private partnership, which he has grown from inception to over 100 experts, and which under his leadership has raised over USD 100m, with spin-off companies and academic partners supported by CCRM securing an additional USD 750m.
Dr. May has extensive experience serving on a diverse range of company boards and industry-focused advisory committees, including at the International Society for Cell Therapy, the Alliance for Regenerative Medicine, and the International Society for Stem Cell Research (ISSCR). Dr. May holds a Ph.D. in Chemical Engineering from the University of Toronto.
AgeX Therapeutics is focused on developing and commercializing innovative therapeutics for human aging.
Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need.
AgeX has two preclinical cell therapy programmes: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
AgeX's revolutionary longevity platform named induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.
AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeX's delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body.
AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults